TwinBeech Capital’s Summit Therapeutics SMMT Stock Holding History

TwinBeech Capital’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-191,119	Closed	-$4.07M	–	820
2025 Q2	$4.07M	Buy	+191,119	New	+$4.36M	0.09%	231

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ACL

APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

TwinBeech Capital's SMMT Position: Q3 2025 in Review

TwinBeech Capital sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 191,119 shares — an estimated $4.07M sold.

TwinBeech Capital first reported a position in SMMT in Q2 2025 and held it in 1 quarter. The position peaked at $4.07M in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

TwinBeech Capital reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
TwinBeech Capital sold 191,119 Summit Therapeutics shares in Q3 2025, an estimated $4.07M.
TwinBeech Capital first reported a position in Summit Therapeutics in Q2 2025 and held it in 1 quarter.
TwinBeech Capital's Summit Therapeutics position peaked at $4.07M in Q2 2025.
232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on TwinBeech Capital's 13F filing for Q3 2025, filed 14 Nov 2025.